Analyzing Geron Corporation (GERN) and Its Rivals
Geron Corporation (NASDAQ: GERN) is one of 293 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Geron Corporation to similar businesses based on the strength of its dividends, analyst recommendations, risk, profitability, earnings, valuation and institutional ownership.
Volatility and Risk
Geron Corporation has a beta of 2.76, meaning that its stock price is 176% more volatile than the S&P 500. Comparatively, Geron Corporation’s competitors have a beta of 6.63, meaning that their average stock price is 563% more volatile than the S&P 500.
This is a summary of current recommendations for Geron Corporation and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Geron Corporation Competitors||745||3048||11536||246||2.72|
Geron Corporation currently has a consensus price target of $4.17, indicating a potential upside of 89.39%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 29.40%. Given Geron Corporation’s higher probable upside, research analysts plainly believe Geron Corporation is more favorable than its competitors.
Insider & Institutional Ownership
38.8% of Geron Corporation shares are owned by institutional investors. Comparatively, 51.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 7.1% of Geron Corporation shares are owned by company insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Geron Corporation and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Geron Corporation Competitors||-5,483.73%||-450.26%||-41.94%|
Earnings & Valuation
This table compares Geron Corporation and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Geron Corporation||$5.91 million||-$26.81 million||-13.75|
|Geron Corporation Competitors||$330.89 million||$94.72 million||-7.24|
Geron Corporation’s competitors have higher revenue and earnings than Geron Corporation. Geron Corporation is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Geron Corporation competitors beat Geron Corporation on 8 of the 12 factors compared.
About Geron Corporation
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Janssen is engaged in the development of Imetelstat with two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the RNA template of telomerase, thereby directly inhibiting telomerase activity.
Receive News & Ratings for Geron Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Corporation and related companies with MarketBeat.com's FREE daily email newsletter.